Special Considerations in the Treatment of Migraine in Women

Christine L. Lay; Susan W. Broner

doi:10.1055/s-2006-939922

Seminars in Neurology, Table of Contents

Semin Neurol 2006; 26(2): 217-222
DOI: 10.1055/s-2006-939922

Special Considerations in the Treatment of Migraine in Women

Christine L. Lay¹ , Susan W. Broner¹

¹The Headache Institute, St. Luke's-Roosevelt Hospital Center, New York, New York

Abstract

ABSTRACT

Nearly 32 million Americans have migraine, 24 million of whom are women who suffer with migraine throughout their lifetimes. Prior to puberty, girls are afflicted with migraine at approximately the same rate as boys, but after puberty there is an emerging female predominance. Although hormones do not entirely explain the epidemiological variation seen in migraine, estrogen certainly plays an important role. Given the hormonal changes occurring throughout a woman's life, there are many opportunities for a hormonal impact on migraine, including menarche, oral contraceptive use, pregnancy, perimenopause, and menopause. The special considerations of migraine in women will be reviewed including epidemiology, pathophysiology, diagnosis, and therapy.

KEYWORDS

Hormones - menstrual migraine - pregnancy - menopause - contraceptives

Full Text

References

REFERENCES

1 Van der Linden J A. De Hemicrania Menstrua. London; Elsevirium 1666
2 Allais G, Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutical strategies. Neurol Sci. 2004; 25(suppl 3) S229-S231
3 Epstein M T, Hockaday J M, Hockaday T D. Migraine and reproductive hormones throughout the menstrual cycle. Lancet. 1975; 1 543-548
4 MacGregor E A. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004; 3 354-361
5 Couturier E G, Bomhof M A, Neven A K, van Duijn N P. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003; 23 302-308
6 Granella F, Sances G, Allais G et al.. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centers. Cephalalgia. 2004; 24 707-716
7 Headache Classification Subcommittee of the International Headache Society . The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004; 24(suppl 1) 139-140
8 Silberstein S D, Merriam G R. Sex hormones and headache. J Pain Symptom Manage. 1993; 8 98-114
9 MacGregor E A. “Menstrual” migraine: towards a definition. Cephalalgia. 1996; 16 11-21
10 Johnson S R. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol. 2004; 104 845-859
11 Somerville B W. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972; 22 355-365
12 Somerville B W. Estrogen-withdrawal migraine. Neurology. 1975; 25 239-250
13 Sargent J, Solbach P, Damasio H et al.. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache. 1985; 25 320-324
14 Al-Waili N S. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res. 2000; 5 176-182
15 Newman L C, Lipton R B, Lay C L, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998; 51 307-309
16 Newman L, Mannix L K, Landy S et al.. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001; 41 248-256
17 Silberstein S D, Elkin A H, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004; 63 261-269
18 Edelson R N. Menstrual migraine and other hormonal aspects of migraine. Headache. 1985; 25 376-379
19 Silberstein S D, Bradley K. DHE-45^® in the prophylaxis of menstrually related migraine. Platform presentation at the IX Migraine Trust International Symposium, London, UK, September 1996 Cephalagia 1996 16:371
20 D'Alessandro R, Gamberini G, Lozito A, Sacquegna T. Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine. Cephalalgia. 1983; 3(suppl 1) 156-158
21 Silberstein S D. The role of sex hormones in headache. Neurology. 1992; 42(suppl 2) 37-42
22 Dennerstein L, Morse C, Burrows G et al.. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988; 2 113-120
23 de Lignieres B, Vincens M, Mauvais-Jarvis P et al.. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed). 1986; 293 1540
24 Calton G J, Burnett J W. Danazol and migraine. N Engl J Med. 1984; 310 721-722
25 O'Dea J P, Davis E H. Tamoxifen in the treatment of menstrual migraine. Neurology. 1990; 40 1470-1471
26 Herzog A G. Continuous bromocriptine therapy in menstrual migraine. Neurology. 1997; 48 101-102
27 Holdaway I M, Parr C E, France J. Treatment of a patient with severe menstrual migraine using the depot LHRH analogue Zoladex. Aust NZJ Obstet Gynaecol. 1991; 31 164-165
28 Murray S C, Muse K N. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and “add-back” therapy. Fertil Steril. 1997; 67 390-393
29 Neri I, Granella F, Nappi R et al.. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993; 17 31-37
30 Martin V, Wenke S, Mandell K et al.. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache. 2003; 43 309-321
31 Dalton K. Migraine and oral contraceptives. Headache. 1976; 15 247-251
32 Bousser M G, Conard J, Kittner S et al.. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptive and Hormone Replacement Therapy. Cephalalgia. 2000; 20 155-156
33 Fox A W, Davis R L. Migraine chronobiology. Headache. 1998; 38 436-441
34 Sances G, Granella F, Nappi R E et al.. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia. 2003; 23 197-205
35 Silberstein S D. Headaches and women: treatment of the pregnant and lactating migraineur. Headache. 1993; 33 533-540
36 Pfaffenrath V, Rehm M. Migraine in pregnancy: what are the safest treatment options?. Drug Saf. 1998; 19 383-388
37 Cupini L M, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex hormone related events in migrainous females: a clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995; 15 140-144
38 Wainscott G, Sullivan F M, Volans G N, Wilkinson M. The outcome of pregnancy in women suffering from migraine. Postgrad Med J. 1978; 54 98-102
39 Fox A W, Chambers C D, Anderson P O, Diamond M L, Spierings E LH. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache. 2002; 42 8-15
40 MacGregor E A. Effects of oral and transdermal estrogen replacement on migraine. Cephalalgia. 1999; 19 124-125
41 Facchinetti F, Nappi R E, Tirelli A et al.. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002; 42 924-929
42 Hodson J, Thompson J, al-Azzawi F. Headache at menopause and in hormone replacement therapy users. Climacteric. 2000; 3 119-124
43 Nappi R E, Cagnacci A, Granella F et al.. Course of primary headaches during hormone replacement therapy. Maturitas. 2001; 38 157-163

Christine L LayM.D.

The Headache Institute, St. Luke's-Roosevelt Hospital Center

1000 Tenth Avenue, Suite 1C-10, New York, NY 10019